Statements (11)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antiviral_drug
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:developedBy |
Bliss Biopharmaceuticals
|
| gptkbp:intendedUse |
gptkb:COVID-19
|
| gptkbp:mechanismOfAction |
neutralizes SARS-CoV-2 virus
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
gptkb:SARS-CoV-2_spike_protein
|
| gptkbp:bfsParent |
gptkb:BLISS_Reference_Manual
gptkb:DEC_BLISS |
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
BLISS-16
|